Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Gaia BioMedicine, a Japan-based cancer immuno-cellular therapeutics developer spun out of Kyushu University, has secured ¥1.3bn ($11.9m) in a series B round backed by Osaka University Venture Capital (OUVC), a vehicle for Osaka University. The round was led by financial services firm Mitsubishi UFJ subsidiary Mitsubishi UFJ Capital’s Life Science Fund 2 and also included…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.